Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Featured Clinical Focus
AMLBiomarker-Driven Lung CancerBone Marrow & SCTBTK Inhibitors: In-FocusCAR T-Cell TherapyChronic Lymphocytic LeukemiaEGFR-Positive Lung CancerEndometrial CancerFollicular LymphomaHCCLung CancerMantle Cell LymphomaMPNsMultiple MyelomaRenal Cell CarcinomaSmall Cell Lung CancerThyroid Cancers
Clinical Focus
View MoreBrain CancerBreast CancerGastrointestinal CancerGenitourinary CancersGynecologic CancersHead & Neck CancersHematologyLeukemiasLung CancerLymphomasMelanomaSarcomaSkin CancersThyroid Cancers
Spotlight
View MoreCase Based Peer PerspectivesCase-Based Roundtable SeriesClinical TrialsPodcastsPrecision MedicineSpecial Reports
NEWS
All NewsClinical FocusSpecial Reports
CONFERENCES
Conference CoverageConference Listing
MEDIA
All VideosCase-Based Peer PerspectivesExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPodcastsPrecision Medicine
PUBLICATIONS
All PublicationsEvolving ParadigmsRoundtable Meetings SpotlightTargeted Therapies in Oncology
CME/CE
RESOURCES
Case-Based Roundtable SeriesClinical TrialsPartnersPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
SUBSCRIBE
eNewsletter
  • About Us
  • Advertise
  • Contact Us
  • CureToday.com
  • CancerNetwork.com
  • OncLive.com
  • OncNursingNews.com
  • Do Not Sell My Information
  • Privacy
  • Terms & Conditions
  • MJHLS Brand Logo

© 2023 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.

Advertisement
Featured Clinical Focus
  • AML
  • Biomarker-Driven Lung Cancer
  • Bone Marrow & SCT
  • BTK Inhibitors: In-Focus
  • CAR T-Cell Therapy
  • Chronic Lymphocytic Leukemia
  • EGFR-Positive Lung Cancer
  • Endometrial Cancer
  • Follicular Lymphoma
  • HCC
  • Lung Cancer
  • Mantle Cell Lymphoma
  • MPNs
  • Multiple Myeloma
  • Renal Cell Carcinoma
  • Small Cell Lung Cancer
  • Thyroid Cancers
Clinical FocusSee All >
  • Brain Cancer
  • Breast Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Gynecologic Cancers
  • Head & Neck Cancers
  • Hematology
  • Leukemias
  • Lung Cancer
  • Lymphomas
  • Melanoma
  • Sarcoma
  • Skin Cancers
  • Thyroid Cancers
SpotlightSee All >
  • Case Based Peer Perspectives
  • Case-Based Roundtable Series
  • Clinical Trials
  • Podcasts
  • Precision Medicine
  • Special Reports
baltimore conference logo
  • About Us
  • Advertise
  • Contact Us
  • CureToday.com
  • CancerNetwork.com
  • OncLive.com
  • OncNursingNews.com
  • Do Not Sell My Information
  • Privacy
  • Terms & Conditions
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.

Examining the Role of Frontline BTKi Monotherapy in CLL

Expert perspectives on the use of frontline BTKi (Bruton's tyrosine kinase inhibitors) monotherapy in the treatment of chronic lymphocytic leukemia (CLL).

EP. 1: Approved BTKi Frontline Treatments for CLL

March 29th 2021

Jennifer R. Brown, MD, PhD, highlights newly FDA approved Bruton’s tyrosine kinase inhibitor (BTKi) monotherapy therapies for the treatment of CLL (chronic lymphocytic leukemia).

EP. 2: Tolerability of Ibrutinib, Zanubrutinib, and Acalabrutinib

March 29th 2021

Citing results from recent trials, Jennifer R. Brown, MD, PhD, compares patient tolerability levels of ibrutinib, zanubrutinib, and acalabrutinib.

EP. 3: Advice for Ibrutinib-Intolerant Patients

March 29th 2021

Jennifer R. Brown, MD, PhD, suggests alternative treatments for patients who experience severe adverse-events from ibrutinib.

EP. 4: Unmet Needs in Frontline Treatment of CLL

March 29th 2021

The shortcomings physicians face in combatting CLL (chronic lymphocytic leukemia) are discussed, in addition to what the high-level updates from the ELEVATE-RR press release may reveal regarding future treatments for CLL.

Advertisement
Advertisement